drugset
drugset / Trial / NCT01875991

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

NCT01875991 ↗

Phase 4 Completed 217 enrolled Amgen
RandomizedCrossoverOpen-labelTreatment

Summary

The study will estimate the preference of rheumatoid arthritis (RA) and Plaque Psoriasis (PsO) patients who self inject etanercept for one of two experimental autoinjectors.

Timeline

Start
2013-06-05
Primary completion
2014-03-04
Completion
2014-03-04

Drugs

EvaluationDrugModalityDoseRoute
Background Etanercept Protein / enzyme biologic 50 mg —

Indications

psoriasis rheumatoid arthritis